We narrowed to 7,159 results for: GFP expression plasmids

#50457-AAV5

Ready-to-use AAV5 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 8, 2019

Academic Institutions and Nonprofits only

#50457-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Sept. 22, 2025

Academic Institutions and Nonprofits only

#50457-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 26, 2021

Academic Institutions and Nonprofits only

#50457-AAV2

Ready-to-use AAV2 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Jan. 17, 2020

Academic Institutions and Nonprofits only

#50465-AAV5.T

Ready-to-use AAV5 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

June 12, 2019

Academic Institutions and Nonprofits only

#50465-AAV8.T

Ready-to-use AAV8 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#50465-AAV9.T

Ready-to-use AAV9 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

May 29, 2019

Academic Institutions and Nonprofits only

#50465-AAV2.T

Ready-to-use AAV2 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 31, 2019

Academic Institutions and Nonprofits only

#50465-AAV11.T

Ready-to-use AAV11 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 16, 2025

Academic Institutions and Nonprofits only

#50465-AAV1.T

Ready-to-use AAV1 trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

July 12, 2019

Academic Institutions and Nonprofits only

#198513-AAV1

Ready-to-use AAV1 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#198513-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#122100-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-GFP (#122100). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-GFP plasmid DNA. EF1a-driven expression of GFP. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#200773-AAV8

Ready-to-use AAV8 particles produced from AAV-cfGFP (#200773). In addition to the viral particles, you will also receive purified AAV-cfGFP plasmid DNA. Syn-driven, cysteine-free GFP (cfGFP) expression. These AAV preparations are suitable purity for injection into animals.

Alexander Dityatev

Ramsaran et al Science. 2023 May 5;380(6644):543-551. d

Nov. 13, 2025

Academic Institutions and Nonprofits only

#37825-CAP-B22

Ready-to-use AAV CAP-B22 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the CAP-B22 serotype, which permits efficient transduction of neurons and astrocytes in the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 8, 2023

Academic Institutions and Nonprofits only

#37825-CAP-B10

Ready-to-use AAV CAP-B10 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the CAP-B10 serotype, which permits efficient transduction of both inhibitory and excitatory neurons in the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 8, 2023

Academic Institutions and Nonprofits only

#37825-AAVrg.T

Ready-to-use AAV Retrograde trial size particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. GFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

July 12, 2019

Academic Institutions and Nonprofits only

#209658-AAV5

Ready-to-use AAV5 particles produced from pAAV.CAGFLEX.(cyto).cpSFGFP.HaloTag (#209658). In addition to the viral particles, you will also receive purified pAAV.CAGFLEX.(cyto).cpSFGFP.HaloTag plasmid DNA. CAG-driven, Cre-dependent expression of cpSFGFP.HaloTag (non-responsive control). These AAV preparations are suitable purity for injection into animals.

Tim Brown, HHMI-JRC Tool Translation Team

Marvin et al Proc Natl Acad Sci U S A. 2024 May 21;12

Oct. 29, 2025

Academic Institutions and Nonprofits only

#50465-AAVrg.T

Ready-to-use AAV Retrograde trial size particles produced from pAAV-hSyn-EGFP (#50465). In addition to the viral particles, you will also receive purified pAAV-hSyn-EGFP plasmid DNA. hSyn-driven EGFP expression. These AAV preparations are suitable purity for injection into animals. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons.

Bryan Roth

July 12, 2019

Academic Institutions and Nonprofits only

#50457-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Nov. 8, 2017

Academic Institutions and Nonprofits only

#98747-AAV5

Ready-to-use AAV5 particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV preparations are suitable purity for injection into animals.

Nathaniel Heintz, Alexander Nectow, Eric Schmidt

Nectow et al Cell Rep. 2017 Apr 18;19(3):655-667. doi

Sept. 28, 2018

Academic Institutions and Nonprofits only

#174112-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-mitoGFP-DIO (#174112). In addition to the viral particles, you will also receive purified pAAV-EF1a-mitoGFP-DIO plasmid DNA. EF1a-driven, Cre-dependent expression of mitochondria-targeted GFP. These AAV preparations are suitable purity for injection into animals.

Maarten Kole

Kole et al Nat Commun. 2022 Dec 9;13(1):7598. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#124364-AAV2

Ready-to-use AAV2 particles produced from pAAV-FLEX-DTR-GFP (#124364). In addition to the viral particles, you will also receive purified pAAV-FLEX-DTR-GFP plasmid DNA. CBA-driven, Cre-dependent expression of DTR-GFP. These AAV preparations are suitable purity for injection into animals.

Eiman Azim, Thomas Jessell

Azim et al Nature. 2014 Apr 17;508(7496):357-63. do

June 16, 2020

Academic Institutions and Nonprofits only

#221463-AAV1

Ready-to-use AAV1 particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#22222-AAV9

Ready-to-use AAV9 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 20, 2018

Academic Institutions and Nonprofits only

#22222-AAV1

Ready-to-use AAV1 particles produced from AAV-FLEX-Arch-GFP (#22222). In addition to the viral particles, you will also receive purified AAV-FLEX-Arch-GFP plasmid DNA. CAG-driven cre-dependent Arch-GFP expression for optogenetic neural inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Chow et al Nature. 2010 Jan 7. 463(7277):98-102.

Feb. 21, 2018

Academic Institutions and Nonprofits only

#79871-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO_EGFP-GFE3 (#79871). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO_EGFP-GFE3 plasmid DNA. EF1a-driven, Cre-dependent expression of GFP-GFE3. These AAV preparations are suitable purity for injection into animals.

Don Arnold

Gross et al Nat Methods. 2016 Jun 6. doi: 10.1038/nm

Nov. 13, 2025

Academic Institutions and Nonprofits only

#98747-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-FLEX-EGFPL10a (#98747). In addition to the viral particles, you will also receive purified pAAV-FLEX-EGFPL10a plasmid DNA. Cre-dependent EGFPL10a (EGFP-tagged ribosomal protein) expression for translating ribosome affinity purification (TRAP). These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Nathaniel Heintz, Alexander Nectow, Eric Schmidt

Nectow et al Cell Rep. 2017 Apr 18;19(3):655-667. doi

Sept. 27, 2023

Academic Institutions and Nonprofits only

#221463-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiPVe4_eGFP (#221463). In addition to the viral particles, you will also receive purified pAAV_BiPVe4_eGFP plasmid DNA. Expression of EGFP under the control of the chandelier cell-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Sept. 23, 2025

Academic Institutions and Nonprofits only

#104061-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified pAAV-CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

March 5, 2019

Academic Institutions and Nonprofits only

#59170-AAV5

Ready-to-use AAV5 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

July 21, 2017

Academic Institutions and Nonprofits only

#59170-AAV1

Ready-to-use AAV1 particles produced from pAAV-Syn-Chronos-GFP (#59170). In addition to the viral particles, you will also receive purified pAAV-Syn-Chronos-GFP plasmid DNA. Syn-driven Chronos-GFP expression for optogenetic neural activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Feb. 7, 2018

Academic Institutions and Nonprofits only

#99039-AAV5

Ready-to-use AAV5 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 21, 2018

Academic Institutions and Nonprofits only

#116869-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-H2B-GFP (#116869). In addition to the viral particles, you will also receive purified pAAV-CAG-H2B-GFP plasmid DNA. CAG-driven expression of H2B-GFP. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Economo et al Nature. 2018 Nov;563(7729):79-84. doi: 1

Nov. 13, 2025

Academic Institutions and Nonprofits only

#122063-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1α1.1-ChrimsonR-GFP (#122063). In addition to the viral particles, you will also receive purified pAAV-EF1α1.1-ChrimsonR-GFP plasmid DNA. EF1a-driven expression of ChrimsonR-GFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Klapoetke et al Nat Methods. 2014 Mar;11(3):338-46. doi:

Aug. 7, 2025

Academic Institutions and Nonprofits only

#99039-AAV1

Ready-to-use AAV1 particles produced from pAAV-CamKII-ArchT-GFP (PV2527) (#99039). In addition to the viral particles, you will also receive purified pAAV-CamKII-ArchT-GFP (PV2527) plasmid DNA. CaMKII-driven ArchT-GFP expression for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Han et al Front Syst Neurosci. 2011;5:18. Epub 201

Feb. 7, 2018

Academic Institutions and Nonprofits only

#112677-AAV8

Ready-to-use AAV8 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Sept. 8, 2020

Academic Institutions and Nonprofits only

#112677-AAV5

Ready-to-use AAV5 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Aug. 26, 2019

Academic Institutions and Nonprofits only

#112677-AAV9

Ready-to-use AAV9 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Sept. 8, 2020

Academic Institutions and Nonprofits only

#112677-AAV1

Ready-to-use AAV1 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Brandon Harvey

Back et al Neuron. 2019 Feb 8. pii: S0896-6273(19)3

Dec. 2, 2019

Academic Institutions and Nonprofits only